These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 27240347)

  • 1. Dendritic-Tumor Fusion Cell-Based Cancer Vaccines.
    Koido S
    Int J Mol Sci; 2016 May; 17(6):. PubMed ID: 27240347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell fusion between dendritic cells and whole tumor cells.
    Koido S; Gong J
    Methods Mol Biol; 2015; 1313():185-91. PubMed ID: 25947665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.
    Tanaka Y; Koido S; Ohana M; Liu C; Gong J
    J Immunol; 2005 Feb; 174(3):1274-80. PubMed ID: 15661883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic-tumor fusion cells in cancer immunotherapy.
    Takakura K; Kajihara M; Ito Z; Ohkusa T; Gong J; Koido S
    Discov Med; 2015 Mar; 19(104):169-74. PubMed ID: 25828520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
    Dolan BP; Gibbs KD; Ostrand-Rosenberg S
    J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of dendritic cell-tumor fusion cells on cancer vaccines - past progress and future strategies.
    Kajihara M; Takakura K; Ohkusa T; Koido S
    Immunotherapy; 2015; 7(10):1111-22. PubMed ID: 26507578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cell-tumor fusion vaccine prevents tumor growth in vivo.
    Kim GY; Chae HJ; Kim KH; Yoon MS; Lee KS; Lee CM; Moon DO; Lee JS; Jeong YI; Choi YH; Park YM
    Biosci Biotechnol Biochem; 2007 Jan; 71(1):215-21. PubMed ID: 17213658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient CTL productivity of modified fusion cells by increase of heat shock protein 70.
    Koide T; Iinuma H; Fukushima R
    Oncol Rep; 2009 Mar; 21(3):737-46. PubMed ID: 19212634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Streptococcal preparation OK-432 promotes fusion efficiency and enhances induction of antigen-specific CTL by fusions of dendritic cells and colorectal cancer cells.
    Koido S; Hara E; Homma S; Torii A; Mitsunaga M; Yanagisawa S; Toyama Y; Kawahara H; Watanabe M; Yoshida S; Kobayashi S; Yanaga K; Fujise K; Tajiri H
    J Immunol; 2007 Jan; 178(1):613-22. PubMed ID: 17182602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC class I and class II and elicits superior antitumor immunity.
    Mitsui H; Inozume T; Kitamura R; Shibagaki N; Shimada S
    J Invest Dermatol; 2006 Aug; 126(8):1804-12. PubMed ID: 16645583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination.
    Wei FQ; Sun W; Wong TS; Gao W; Wen YH; Wei JW; Wei Y; Wen WP
    J Exp Clin Cancer Res; 2016 Jan; 35():18. PubMed ID: 26795730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
    Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
    Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG
    Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer immunotherapy by fusions of dendritic cells and tumor cells.
    Koido S; Hara E; Homma S; Ohkusa T; Gong J; Tajiri H
    Immunotherapy; 2009 Jan; 1(1):49-62. PubMed ID: 20635973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
    Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
    Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
    Homma S; Komita H; Sagawa Y; Ohno T; Toda G
    Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of fusion cells from patient-derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical use.
    Koido S; Nikrui N; Ohana M; Xia J; Tanaka Y; Liu C; Durfee JK; Lerner A; Gong J
    Gynecol Oncol; 2005 Nov; 99(2):462-71. PubMed ID: 16137749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma.
    Raje N; Hideshima T; Davies FE; Chauhan D; Treon SP; Young G; Tai YT; Avigan D; Gong J; Schlossman RL; Richardson P; Kufe DW; Anderson KC
    Br J Haematol; 2004 May; 125(3):343-52. PubMed ID: 15086415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells.
    Bernstein MB; Chakraborty M; Wansley EK; Guo Z; Franzusoff A; Mostböck S; Sabzevari H; Schlom J; Hodge JW
    Vaccine; 2008 Jan; 26(4):509-21. PubMed ID: 18155327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J; Saffold S; Cao X; Krauss J; Chen W
    J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.